Health Care·Biotechnology·$24.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $4.36 | N/A | +24.39% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $4.36 | N/A | +24.39% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a positive outlook regarding their product pipeline. However, they did not provide specific guidance for future quarters.
Management highlighted strong performance in their key product areas.
They expressed confidence in their ongoing research and development efforts.
United Therapeutics reported better-than-expected earnings per share, which indicates strong operational performance. However, the stock fell by over 5% on the day, likely due to the absence of revenue figures and forward guidance. Investors may be cautious as they await more detailed information on future performance and product developments.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
KLA CORP
Jul 30, 2018